Hologic, Inc. (NASDAQ:HOLX) Receives $84.62 Consensus PT from Analysts

Shares of Hologic, Inc. (NASDAQ:HOLX) have received a consensus recommendation of “Hold” from the seventeen brokerages that are presently covering the stock, MarketBeat Ratings reports. Eleven analysts have rated the stock with a hold recommendation, five have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $84.62.

Several equities research analysts have issued reports on the company. BNP Paribas raised Hologic to a “strong-buy” rating in a report on Tuesday, December 10th. Wolfe Research assumed coverage on Hologic in a report on Friday, December 13th. They set a “peer perform” rating for the company. Royal Bank of Canada cut their price target on Hologic from $88.00 to $85.00 and set a “sector perform” rating for the company in a report on Thursday, February 6th. Evercore ISI cut their price target on Hologic from $76.00 to $73.00 and set an “in-line” rating for the company in a report on Thursday, February 6th. Finally, Leerink Partnrs downgraded Hologic from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 6th.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. State Street Corp increased its position in shares of Hologic by 0.8% in the third quarter. State Street Corp now owns 10,409,327 shares of the medical equipment provider’s stock worth $847,944,000 after purchasing an additional 81,057 shares during the period. Geode Capital Management LLC increased its position in shares of Hologic by 2.6% in the fourth quarter. Geode Capital Management LLC now owns 5,732,131 shares of the medical equipment provider’s stock worth $412,159,000 after purchasing an additional 144,838 shares during the period. FMR LLC increased its position in shares of Hologic by 64.0% in the third quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider’s stock worth $453,940,000 after purchasing an additional 2,174,093 shares during the period. Victory Capital Management Inc. increased its position in shares of Hologic by 0.5% in the fourth quarter. Victory Capital Management Inc. now owns 4,917,551 shares of the medical equipment provider’s stock worth $354,506,000 after purchasing an additional 24,358 shares during the period. Finally, Mitsubishi UFJ Asset Management Co. Ltd. increased its position in shares of Hologic by 3.0% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,403,220 shares of the medical equipment provider’s stock worth $322,272,000 after purchasing an additional 129,035 shares during the period. Institutional investors own 94.73% of the company’s stock.

Hologic Trading Down 0.7 %

NASDAQ HOLX opened at $60.70 on Friday. The company has a market cap of $13.62 billion, a PE ratio of 19.15, a PEG ratio of 2.14 and a beta of 0.97. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. Hologic has a 12 month low of $60.33 and a 12 month high of $84.67. The stock has a 50 day moving average of $67.65 and a 200-day moving average of $74.94.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. On average, equities research analysts anticipate that Hologic will post 4.28 EPS for the current fiscal year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.